Imaging vitiligo lesions with polarized, sub-ultraviolet, and ultraviolet dermoscopy
Official title: Evaluation of Morphological Findings Related to Activity, Stability, and Repigmentation in Vitiligo Lesions Using Polarized Dermoscopy, Sub-Ultraviolet Reflectance Dermoscopy, and Ultraviolet Fluorescence Dermoscopy: A Cross-Sectional Observational Imaging Study
Run by Istanbul Training and Research Hospital · NCT07846969 · Data updated 2026-11-12
This study tests whether advanced light-based skin imaging can reveal details of vitiligo spots in adults more clearly than standard polarized dermoscopy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Istanbul Training and Research Hospital Government |
| Locations | 1 site (Istanbul) |
| Status | Recruiting |
| Started | July 1, 2026 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | September 29, 2026 |
| Trial ID | NCT07846969 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older with a clinical diagnosis of vitiligo and at least one non-genital lesion suitable for high-quality dermoscopic imaging.
✕Probably not a fit
Participants with lesions that are not adequately captured by imaging or with unstable/calcified lesions may derive no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, cross-sectional observational study will image 1 to 3 non-genital vitiligo lesions per adult participant during one visit using three imaging methods: polarized dermoscopy, sub-ultraviolet reflectance dermoscopy, and ultraviolet fluorescence dermoscopy. A Casio DZ-D100-AEA device captures multiple image types from the same lesion area to improve within-lesion comparison, while DermLite DL5 provides ultraviolet images. Dermatologists will review coded images and score visibility of selected skin features; data on disease duration, course, treatment status, and patient-reported lesion changes will be collected. The study does not involve any invasive procedures, blood tests, or treatments and aims to determine if these imaging modalities offer additional detail beyond standard dermoscopy for vitiligo activity and stability assessment.
Why it matters
Potential benefit: If successful, the imaging approach could improve noninvasive visualization of vitiligo activity and stability, aiding clinical assessment and monitoring.
How similar studies have gone: Previous imaging studies in dermatology have shown value for noninvasive lesion characterization, but this specific combination of imaging modalities for vitiligo is exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years or older * Clinical diagnosis of vitiligo * Presence of at least one clinically suitable non-genital vitiligo lesion for dermoscopic imaging * Ability and willingness to provide written informed consent Exclusion Criteria: * Uncertain clinical diagnosis of vitiligo or presence of another hypopigmented or depigmented disorder that may interfere with lesion evaluation * Absence of any clinically suitable non-genital vitiligo lesion for imaging * Inability to cooperate with the imaging procedure * Refusal or inability to provide written informed consent
Where it's running
-
University of Health Sciences Istanbul Training and Research Hospital
Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Sueda Şanlı Arıkan, Dermatology Resident Physician
- Email: sueda.sanli.md@gmail.com
- Phone: +90 5362483355
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
crisaborole 2% versus tacrolimus 0.1% with light therapy for facial vitiligo
This study tests whether applying crisaborole 2% ointment can improve stable facial vitiligo in children and adults and whether it is as safe and effective as tacrolimus 0.1% when combined with light therapy.
-
MH004 Ointment in non-segmental vitiligo: a phase 3 trial
A 12-month randomized trial tests MH004 ointment to see if it helps facial vitiligo more than a placebo in people aged 12 to 75.
-
NSV: Vitiligo Drug Safety and Effectiveness Registry for Adults and Teens
This registry tracks adults and teens with nonsegmental vitiligo to see how usual treatments work and how safe they are over time in real-world dermatology care.
-
D-2570 in Non-Segmental Vitiligo (Phase 2)
This study tests whether D-2570 can improve skin discoloration in adults with non-segmental vitiligo compared with a placebo.
-
LY4005130 for adults with non-segmental vitiligo
This study will test whether intravenous LY4005130 is safe and what side effects it may cause in adults with non-segmental vitiligo.
-
Micro-needling with 5‑fluorouracil versus strong topical steroid for limited vitiligo
This trial will test whether micro-needling plus 5‑fluorouracil or a potent topical steroid works better to restore pigment in people with limited, stable vitiligo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.